Ghoul
Member
I’ve had a tiny, rough circular patch of skin on my arm since I was a child. Like a tiny island of psoriasis. Nothing ever helped it, and frankly it was no big deal according to dermatologists, so I left it alone. A few months after starting Pitavastatin it disappeared. I was trying to see if there might be a connection, and fell down an interesting rabbit hole I somehow missed before.
If lowering lipids isn’t enough of a motivator to use this statin with its uniquely low side effect, athlete friendly profile, there’s a growing body of evidence it prevents and slows cancer by making cancer cells more susceptible to death (apoptosis), instead of living eternally like zombies.
Something that may help offset the faster development of tumors caused by higher IGF-1 levels, which may help offset the increased cancer risk in rHGH users.
Other statins share this property, but its by far strongest in Pitavastatin, with some oncologists now prescribing it off label in chemo patients because it appears to result in better outcomes by making cancer cells, more susceptible to being killed:
1. Skin cancer
www.onclive.com
2. Lung cancer
pubmed.ncbi.nlm.nih.gov
3. Breast cancer
pmc.ncbi.nlm.nih.gov
4. Pancreatic cancer
pubmed.ncbi.nlm.nih.gov
5. Liver cancer
www.dovepress.com
6. Ovarian cancer
www.nature.com
7. Cervical cancer
8. Colon cancer
www.frontiersin.org
9. Oral cancer
pubmed.ncbi.nlm.nih.gov
10. Triple-negative breast cancer
pubmed.ncbi.nlm.nih.gov
11. Gynecologic cancers
12. Solid tumors
pmc.ncbi.nlm.nih.gov
If lowering lipids isn’t enough of a motivator to use this statin with its uniquely low side effect, athlete friendly profile, there’s a growing body of evidence it prevents and slows cancer by making cancer cells more susceptible to death (apoptosis), instead of living eternally like zombies.
Something that may help offset the faster development of tumors caused by higher IGF-1 levels, which may help offset the increased cancer risk in rHGH users.
Other statins share this property, but its by far strongest in Pitavastatin, with some oncologists now prescribing it off label in chemo patients because it appears to result in better outcomes by making cancer cells, more susceptible to being killed:
1. Skin cancer
Pitavastatin Offers Therapeutic Potential in Cancers Arising From Chronic Inflammation | OncLive
Pitavastatin, an FDA-approved statin, may inhibit pathways that contribute to IL-33 production, which has been shown to contribute to cancer development.
2. Lung cancer
Cholesterol-lowering drug pitavastatin targets lung cancer and angiogenesis via suppressing prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signaling - PubMed
Therapeutic agents that target both tumor cell and vascular endothelial cell may achieve additional anti-tumor efficacy, particularly in lung cancer due to the critical roles of angiogenesis during lung cancer progression and metastasis. In this work, we showed that pitavastatin, a novel...
3. Breast cancer
Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway - PMC
Bone is a frequent site of metastasis from breast cancer, and a desirable drug could suppress tumor growth as well as metastasis-linked bone loss. Currently, no drug is able to cure breast cancer–associated bone metastasis. In this study, we focused ...
4. Pancreatic cancer
Pitavastatin and metformin synergistically activate apoptosis and autophagy in pancreatic cancer cells - PubMed
Pancreatic cancer is the seventh leading cause of cancer-related deaths globally. Metformin is the standard first-line of treatment for hyperglycemia in Type 2 diabetes, whereas pitavastatin is a cholesterol-lowering drug used to prevent cardiovascular diseases. Both these agents evidently exert...
5. Liver cancer
Pitavastatin suppressed liver cancer cells in vitro and in vivo | OTT
Pitavastatin suppressed liver cancer cells in vitro and in vivo He-Yi You, Wei-Jian Zhang, Xue-Meng Xie, Zhi-Hai Zheng, Heng-Liang Zhu, Fei-Zhao Jiang Department of Telescopic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China Abstract...
6. Ovarian cancer
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer - Scientific Reports
Pre-clinical and retrospective studies of patients using statins to reduce plasma cholesterol have suggested that statins may be useful to treat cancer. However, prospective clinical trials have yet to demonstrate significant efficacy. We have previously shown that this is in part because a...
7. Cervical cancer
8. Colon cancer
Frontiers | Pitavastatin Induces Cancer Cell Apoptosis by Blocking Autophagy Flux
Statins, a class of lipid-lowering drugs, are used in drug repositioning for treatment of human cancer. However, the molecular mechanisms underlying statin-i...
9. Oral cancer
Pitavastatin Induces Cancer Cell Apoptosis by Blocking Autophagy Flux - PubMed
Statins, a class of lipid-lowering drugs, are used in drug repositioning for treatment of human cancer. However, the molecular mechanisms underlying statin-induced cancer cell death and autophagy are not clearly defined. In the present study, we showed that pitavastatin could increase apoptosis...
10. Triple-negative breast cancer
Pitavastatin induces autophagy-dependent ferroptosis in MDA-MB-231 cells via the mevalonate pathway - PubMed
Triple-negative breast cancer (TNBC) is more prone to recurrence and metastasis relative to other subtypes of breast cancer, leading to an extremely poor prognosis. The increasing potential chemoresistance of TNBC patients is mainly due to that tumor cells escape from apoptosis. In recent years...
11. Gynecologic cancers
12. Solid tumors
The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study - PMC
The significance of statin treatment for the reduction of cardiovascular (CV) disease has been reported, whereas other reports have also described anti-cancer properties associated with the class effect of statins. However, the differences in ...
Last edited:
